Table 1.
Study Characteristics
| First Author/Year of Publication | Country of the study | Year of Study | Study Design | Dose of Sacubitril /Valsartan |
Follow-up Time | Number of Patients | Age, yrs | Male, n (%) | Dialysis Modality | Type of Heart Failure and LVEF of Included Patients | Comorbidities/Medications (n) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Niu et al.,26 2022 | Taiwan | 2019 | Case-control study | 97 mg/103 mg twice daily | 12 mo | 49 | Mean 60.96 (SD 12.09) |
32 (78.5%) | HD (23 patients) and PD (16 patients) | HFrEF, LVEF <40% | Hypertension: n = 23, Diabetes: n = 12, CAD: n = 13. B-blocker: n = 16, CCB: n = 5, ACEI/ARB: n = 0, MCA: n = 2 |
| Feng et al.,27 2022 | China | 2019–2020 | Prospective, observational, self-controlled study | 50–100 mg twice a day | 18 mo | 11 | Median 50 (IQR 39–72) |
5 (45%) | HD | HFrEF and HFmrEF, LVEF 40% and 40–50% | N/A |
| Fu et al.,28 2021 | China | 2018–2019 | Retrospective, observational self-controlled study | 50–100 mg twice a day | 3–12 mo | 21 | Median 55 (IQR 38–61) |
14 (67%) | PD | HFpEF, LVEF >50% | Hypertension: n = 21, Diabetes: n = 5, CAD: n = 21 B-blocker: n = 11, CCB: n = 21, ACEI/ARB: n = 6, Diuretic: n = 10 |
| Guo et al.,29 2022 | China | 2019–2021 | Retrospective, observational self-controlled study | 200 mg twice a day | 3–12 mo | 247 | Mean 45.8 (SD 13.7) |
154 (62%) | HD | HFpEF, LVEF >50% | Hypertension: n = 23, Diabetes: n = 12, CAD: n = 13 B-blocker: n = 185, CCB: n = 213, ACEI/ARB: n = 221, MCA: n = 12 |
| Hsiao et al.,30 2022 | Taiwan | 2016–2018 | Retrospective, observational cohort study | N/A | Period from the cohort entry date until the first occurrence of an outcome, day of mortality, the last outpatient visits or discharge date, the end of the study period or at 12th month, whichever occurred first | 618 | N/A | N/A | Nonspecified | HFrEF, LVEF<40% | N/A |
| Lee et al.,13 2020 | Korea | 2017–2019 | Retrospective, observational self-controlled study | 90 ± 43 mg/day at baseline and 123 ± 62 mg/day at last follow-up | Median 132 days, (IQR 77–132) | 23 | Mean 60 (SD 17) |
20 (85%) | HD and PD | HFrEF, LVEF<35% | Hypertension: n = 18, Diabetes: n = 89, CAD: n = 21 B-blocker: n = 23, ACEI/ARB: n = 23 |
| Ma et al.,31 2023 | China | 2018–2021 | Retrospective, observational cohort study | 50 mg/time, twice/day, and gradually increased to 100 mg/time, twice/day | 6–12 mo | 99 | Mean 52 (SD 13) |
67 (56%) | PD | HFpEF, LVEF >50% | Diabetes: n = 23 B-blocker: n = 40, CCB: n = 45, Diuretic: n = 35 |
| Wang et al.,32 2022 | China | Prospective, observational, self-controlled study | 50–100 mg/day | 12 wks | 18 | Mean 53.6 (SD 14.5) |
15 (83%) | HD | HFpEF and HFrEF, LVEF in 1 patient <40%, 3 patients 40%–50%, 15 patients >50% | CAD: n = 2, B-blocker: n = 18, CCB: n = 16, ACEI/ARB: n = 18 |
|
| Lihua et al.,33 2021 | China | 2018–2019 | Prospective, observational, self-controlled | 135–308 mg /day | 12 mo | 110 | Mean 52 (SD 14.8) |
65 (59%) | HD | HFrEF, LVEF <40% | CAD: n = 6, B-blocker: n = 41, CCB: n = 105, ACEI/ARB: n = 102, MCA: n = 12, Diuretic: n = 6 |
| Wen et al.,34 2022 | China | 2020–2021 | Retrospective, observational self-controlled study | 50–200 mg/day | 6 mo | 54 | Mean 50.9 (SD 14.6) |
29 (53%) | HD | HFrEF, LVEF <40% | B-blocker: n = 51 |
| Zhang et al.,35 2022 | China | 2020–2021 | Retrospective, observational self-controlled study | 100 mg twice a day | 7 d | 47 | Mean 45.9 (SD 12.4) |
28 (60%) | PD | Nonspecified | Hypertension: n = 42, Diabetes, n = 10 ACEI/ARB: n = 27, Diuretic: n = 12 |
| Zhao et al.,36 2022 | China | 2019–2021 | Retrospective, observational cohort study | 100 mg twice a day | 3 mo | 122 | Mean 49.13 (SD 15.4) | 75 (75%) | HD | Nonspecified | Hypertension: n = 69, Diabetes: n = 17, CAD: n = 13 |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; d, day; HD, hemodialysis; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection; IQR, interquartile range; LVEF, left ventricular ejection fraction; MCA, mineralocorticoid antagonist; mo, month; PD, peritoneal dialysis.